{"organizations": [], "uuid": "a50f208d3fe65333cab00bba6919c46a11e6b376", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 11, "shares": 11, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://si.wsj.net/public/resources/images/BN-XU884_3alz_SOC_20180311153005.jpg", "site_section": "http://www.wsj.com/xml/rss/3_7041.xml", "section_title": "WSJ.com: Opinion", "url": "https://www.wsj.com/articles/cures-welcome-at-fda-1520803007", "country": "US", "domain_rank": 387, "title": "Cures Welcome at FDA", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T00:16:00.000+02:00", "replies_count": 0, "uuid": "a50f208d3fe65333cab00bba6919c46a11e6b376"}, "author": "The Editorial Board", "url": "https://www.wsj.com/articles/cures-welcome-at-fda-1520803007", "ord_in_thread": 0, "title": "Cures Welcome at FDA", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Few conditions are as wrenching as the destruction of memory known as Alzheimer’s, and few diseases have so eluded drug companies and researchers looking for a cure. So it’s welcome news that the Food and Drug Administration is inviting more innovation, and more broadly revamping the agency’s review process.\nFDA recently updated its scientific thinking on early Alzheimer’s, along with other neurological conditions, and this matters because such draft guidance informs industry and academic efforts. One reality of Alzheimer’s... ", "external_links": [], "published": "2018-03-12T00:16:00.000+02:00", "crawled": "2018-03-12T08:09:58.002+02:00", "highlightTitle": ""}